AI Article Synopsis
- The study involved 76 patients with myelodysplastic syndromes (MDS) who were monitored for changes in their karyotypes over a period of up to 82 months.
- The rate of significant karyotype changes was similar between patients with normal karyotypes at the start and those with existing clonal abnormalities, at around 24.5% and 26.1%, respectively.
- It was found that most cytogenetic changes did not correlate with worsening disease or lower survival rates, suggesting that only specific changes are linked to disease progression, while many others are of minimal clinical importance.
Article Abstract
We performed prospective sequential cytogenetic studies in 76 patients with myelodysplastic syndromes (MDS) followed up to 82 months. Their karyotypes were followed routinely, regardless of clinical status. The incidence of evolutive karyotypes was similar in patients with a normal karyotype at referral and in patients with clonal abnormalities at diagnosis (24.5 and 26.1%, respectively). We did not find association between karyotype evolution and leukemic transformation or reduced survival, since the majority of secondary cytogenetic changes in evolutive karyotypes of our patients were aberrations with good or intermediate prognosis. Therefore, we concluded that only particular cytogenetic events are related to disease progression, while others represent secondary changes of little biologic and prognostic significance.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!